Avalo Reports Third Quarter 2024 Financial Results and Recent Business Updates

Provided By GlobeNewswire

Last update: Nov 7, 2024

WAYNE, Pa. and ROCKVILLE, Md., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced business updates and financial results for the third quarter of 2024.